Abstract: The invention is a method of inhibiting cancer growth, by inhibiting cellular proliferation, invasiveness, or metastasis, or by inducing cytotoxicity against cancer in mammals. The method employs 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) and other functionally related chemically modified, preferably non-antibacterial, tetracycline compounds to inhibit cancer growth. The method is particularly effective to inhibit the establishment, growth, and metastasis of solid tumors, such as tumors derived from colon cancer cells, breast cancer cells, melanoma cells, prostatic carcinoma cells, or lung cancer cells.
Type:
Grant
Filed:
January 15, 1998
Date of Patent:
August 8, 2000
Inventors:
Lorne M. Golub, Thomas F. McNamara, Nungavaram S. Ramamurthy, Hsi-Ming Lee, Sanford Simon, Balakrishna L. Lokeshwar, Marie G. Selzer, Norman L. Block
Abstract: Compositions comprising anti-CD45RB antibodies are provided for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases.
Type:
Grant
Filed:
February 4, 1998
Date of Patent:
August 8, 2000
Assignee:
Reasearch Corporation Technologies, Inc.
Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
Type:
Grant
Filed:
November 12, 1997
Date of Patent:
August 8, 2000
Assignee:
Fox Chase Cancer Center
Inventors:
Erica A. Golemis, Susan F. Law, Joanne Estojak
Abstract: A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 25, 2000
Assignee:
Institute of Virology, Slovak Academy of Sciences
Inventors:
Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
Abstract: The invention provides a human E25a protein which is upregulated in cancerous cells, including those of hormone refractory prostate cancer, colon cancer, breast cancer or other cancers of epithelial origin. The invention also provides nucleic acid molecules encoding E25a protein, nucleic acid probes which hybridize with nucleic acid molecules encoding E25a protein, and antibodies which bind E25a protein. E25a protein and its related molecules can be useful as diagnostic markers of cancer, including hormone refractory prostate cancer, and as specific therapeutic targets in this disease. The invention also provides methods for diagnosing cancer, including hormone refractory prostate cancer.
Type:
Grant
Filed:
September 5, 1997
Date of Patent:
July 25, 2000
Assignee:
The Regents of the University of California
Inventors:
Robert E. Reiter, Owen N. Witte, Charles L. Sawyers
Abstract: The present invention is methods and compositions including a photoactivated antibody that is capable of generating or increasing an immune response.
Type:
Grant
Filed:
June 17, 1997
Date of Patent:
July 11, 2000
Assignee:
Altarex, Inc.
Inventors:
Thomas R. Sykes, Ragupathy Madiyalakan, Richard P. Baum, Antoine A. Noujaim
Abstract: Human nm23 DNA and protein is disclosed as well as antibodies which recognize human nm23 protein. The DNA and antibodies may be used to detect nm23 in human tumors to predict the malignancy potential of such tumors.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 11, 2000
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Charles Richter King, Patricia Schriver Steeg, Lance A. Liotta
Abstract: A non-naturally occurring peptide derived from EGF-like domains of NDF/heregulin protein isoforms is used to stimulate the proliferation of cells in the sensory epithelium of the inner ear. A monoclonal antibody against adult rat utricular epithelium is also described.
Abstract: Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide complex on the surfaces of the cells. Methods are provided for using such acid-eluted T cell epitopes, preferably obtained from a patient's tumor, and autologous dendritic cells as the basis for antitumor vaccines.
Abstract: Provided for use in site-directed chemotherapy are compositions comprising chemotherapeutic agents targeted to either arrested metastatic cells via a cell-surface marker associated with metastasis; or are targeted to type 1 endothelial cells of the tissue comprising the organ site at which metastatic cells arrest such that (a) any arrested metastatic tumor cells are then exposed to the chemotherapeutic agent, and/or (b) the endothelial cells are altered thereby inhibiting the ability of the metastatic tumor cells to arrest, survive or proliferate in that site. Also provided are methods of site-directed chemotherapy of metastatic cells of non-lymphoid tumor origin. Site-directed chemotherapy comprises introducing a therapeutically effective amount of a chemotherapeutic agent directly into a vascular access of the organ having, or suspected of having, arrested metastatic cells thereby concentrating the therapy in the prometastatic territories of the treated organ.
Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.
Type:
Grant
Filed:
July 8, 1997
Date of Patent:
June 6, 2000
Assignee:
Stryker Biotech
Inventors:
William K. Jones, Ronald F. Tucker, David C. Rueger, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath
Abstract: The invention relates to hydroxyproline-rich glycoproteins, which can be obtained by acid alcohol extraction from Taxus supp., Gingko biloba, Lycopersicum esculentum and Daucus carota cell cultures, having the following characteristics: average molecular weight 20,000 Daltons with variability interval 12,000 to 38,000, determined by means of gel permeation and electrophoresis; high solubility in water.
Abstract: Disclosed is a chimeric isoprenoid synthase polypeptide including a first domain from a first isoprenoid synthase joined to a second domain from a second, heterologous isoprenoid synthase, whereby the chimeric isoprenoid synthase is capable of catalyzing the production of isoprenoid reaction products that are not produced in the absence of the second domain of the second, heterologous isoprenoid synthase. Also disclosed is a chimeric isoprenoid synthase polypeptide including an asymmetrically positioned homologous domain, whereby the chimeric isoprenoid synthase is capable of catalyzing the production of isoprenoid reaction products that are not produced when the domain is positioned at its naturally-occurring site in the isoprenoid synthase polypeptide.
Type:
Grant
Filed:
August 14, 1998
Date of Patent:
June 6, 2000
Assignee:
Board of Trustees of the University of Kentucky
Abstract: HE8AN36 potypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HE8AN36 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
Abstract: Disclosed are novel autoantigens and methods useful in the detection of autoantibodies in persons that have developed, or are at risk of developing, autoimmune hypoparathyroidism. The novel autoantigens of the subject invention may be used to achieve early diagnosis and treatmcnt of autoimmune hypoparathyroidism, and possibly other autoimmune diseases which arc frequently associated with autoimmune hypoparathyroidism.
Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.
Abstract: An alkanethiol monolayer membrane is formed on a substrate having an Au layer using Au--S bonding, and a second layer constructed by a monolayer lipid membrane is formed on its surface to form a BLM. A gel layer is formed using agarose on the side of the BLM having the second monolayer lipid layer. In addition, a polymer layer is formed using the amino acid poly-L-lysine between the surface of the monolayer lipid membrane and the gel layer to immobilize the BLM. The use of this supporting constitution for holding and immobilizing the membrane extends the life-span of the BLM, while the gel layer keeps the electrolyte solution required for maintaining flexibility of the membrane and activating protein on the surface of the BLM. In addition, a BLM having a life-span of one month or more is obtained by arranging a membrane supporting portion that minimizes lifting of the membrane molecules due to buoyancy above the BLM arranged upright in an aqueous system.
Abstract: A human mammary transforming protein and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for inhibiting such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.
Abstract: The invention is directed to inter alia two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to affinity screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific affinity for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. These methods result in polyclonal libraries of antibodies and other polypeptides for use, e.g., as diagnostic or therapeutic reagents.
Type:
Grant
Filed:
April 4, 1997
Date of Patent:
May 2, 2000
Assignee:
Biosite Diagnostics, Inc.
Inventors:
Joe Buechler, Gunars Valkirs, Jeff Gray
Abstract: Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative to initiate in the mammal a cytotoxic T cell response against cells infected with a preselected intracellular pathogen. Also disclosed are methodologies for preparing and administering vaccines containing such stress protein-peptide complexes.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
April 11, 2000
Assignee:
Mount Sinai School of Medicine of New York University